Platelet Function or Genetic Testing for Guiding De-Escalation of Anti-Platelet Therapy: The Jury is Still Out

Dominick J. Angiolillo

doi:10.1055/s-0038-1668546

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2018; 118(09): 1509-1511
DOI: 10.1055/s-0038-1668546

Invited Editorial Focus

Georg Thieme Verlag KG Stuttgart · New York

Platelet Function or Genetic Testing for Guiding De-Escalation of Anti-Platelet Therapy: The Jury is Still Out

Authors

Dominick J. Angiolillo

¹University of Florida College of Medicine, University of Florida, Jacksonville, Florida, United States

Abstract

Full Text

References

References
1 Sibbing D, Angiolillo DJ, Huber K. Antithrombotic therapy for acute coronary syndrome: past, present and future. Thromb Haemost 2017; 117 (07) 1240-1248
2 Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015; 12 (01) 30-47
3 Moon JY, Franchi F, Rollini F, Angiolillo DJ. Evolution of coronary stent technology and implications for duration of dual antiplatelet therapy. Prog Cardiovasc Dis 2018; 60 (4-5): 478-490
4 Capodanno D, Mehran R, Valgimigli M. , et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol 2018; 15 (08) 480-496
5 Angiolillo DJ, Rollini F, Storey RF. , et al. International expert consensus on switching platelet P2Y₁₂ receptor-inhibiting therapies. Circulation 2017; 136 (20) 1955-1975
6 Aradi D, Kirtane A, Bonello L. , et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015; 36 (27) 1762-1771
7 Cuisset T, Deharo P, Quilici J. , et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 2017; 38 (41) 3070-3078
8 De Luca L, D'Ascenzo F, Musumeci G. , et al. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention 2017; 13 (04) 459-466
9 Franchi F, Rollini F, Rivas Rios J. , et al. Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease: results of the SWAP-4 study. Circulation 2018; 137 (23) 2450-2462
10 Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 2016; 13 (01) 11-27
11 Sibbing D, Aradi D, Jacobshagen C. , et al; TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017; 390 (10104): 1747-1757
12 Sibbing D, Gross L, Trenk D. , et al. TROPICAL-ACS Investigators. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial. Eur Heart J 2018;
13 Angiolillo DJ. Dual antiplatelet therapy guided by platelet function testing. Lancet 2017; 390 (10104): 1718-1720
14 Moon JY, Franchi F, Rollini F. , et al. Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Rev Clin Pharmacol 2018; 11 (02) 151-164
15 Cavallari LH, Franchi F, Rollini F. , et al. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. J Transl Med 2018; 16 (01) 92
16 Gross L, Trenk D, Jacobshagen C. , et al TROPICAL-ACS Investigators. Genotype-phenotype association and impact on outcomes following guided de-escalation of antiplatelet treatment in ACS patients. Thromb Haemost 2018; 118 (08)